$2.29
8.03% day before yesterday
Nasdaq, Dec 27, 10:03 pm CET
ISIN
US12674W1099
Symbol
CABA
Sector
Industry

Cabaletta Bio Inc Stock price

$2.29
-0.72 23.92% 1M
-5.05 68.80% 6M
-20.41 89.91% YTD
-21.07 90.20% 1Y
-1.82 44.28% 3Y
-11.53 83.43% 5Y
-7.71 77.10% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.20 8.03%
ISIN
US12674W1099
Symbol
CABA
Sector
Industry

Key metrics

Market capitalization $111.93m
Enterprise Value $-55.86m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.67
P/B ratio (TTM) P/B ratio 0.64
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-114.50m
Free Cash Flow (TTM) Free Cash Flow $-83.57m
Cash position $183.01m
EPS (TTM) EPS $-2.16
P/E forward negative
Short interest 7.84%
Show more

Is Cabaletta Bio Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Cabaletta Bio Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Cabaletta Bio Inc forecast:

10x Buy
83%
2x Hold
17%

Analyst Opinions

12 Analysts have issued a Cabaletta Bio Inc forecast:

Buy
83%
Hold
17%

Financial data from Cabaletta Bio Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 1.58 1.58
68% 68%
-
-1.58 -1.58
68% 68%
-
- Selling and Administrative Expenses 22 22
191% 191%
-
- Research and Development Expense 89 89
77% 77%
-
-113 -113
79% 79%
-
- Depreciation and Amortization 1.58 1.58
68% 68%
-
EBIT (Operating Income) EBIT -115 -115
69% 69%
-
Net Profit -104 -104
67% 67%
-

In millions USD.

Don't miss a Thing! We will send you all news about Cabaletta Bio Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cabaletta Bio Inc Stock News

Positive
Seeking Alpha
2 months ago
I am buying Cabaletta Bio shares as a speculative play on upcoming clinical trial updates for innovative CAR-T therapies. Despite high volatility in 2024 and the potential for total investment loss, the company's strong cash position and lack of recent selling point to a bullish outlook. Super-positive testing results announced in mid-November would trigger significant stock gains, with the pos...
Neutral
GlobeNewsWire
3 months ago
PHILADELPHIA, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced two presentations at the upcoming American College of Rheumatology (ACR) Convergence 2024, which is being held at the...
Neutral
GlobeNewsWire
4 months ago
PHILADELPHIA, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in the following investor conferences in September:
More Cabaletta Bio Inc News

Company Profile

Cabaletta Bio, Inc. operates as a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in April 2017 and is headquartered in Philadelphia, PA.

Head office United States
CEO Steven Nichtberger
Employees 103
Founded 2017
Website www.cabalettabio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today